NTRK1 and renal cell carcinoma: A recent phase III trial (METEOR) showed that cabozantinib, an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potent activity against multiple RTKs (MET, RET, VEGFR2, FLT3 and c-KIT) and Tyro3, Axl and Mertk (TAM) RTKs [6] had a significant clinical benefit for bone metastatic RCC patients [7].